Galapagos COO steps down amid sweeping corporate overhaul

15 April 2025

Galapagos (Euronext: GLPG) said on Tuesday that its chief financial officer and chief operating officer Thad Huston will leave the company on August 1, 2025, to return to the USA for personal and professional reasons.

Mr Huston joined the Belgian biotech in 2023 from Kite Pharma to support its pivot toward cell therapy. The company said a successor will be announced in the coming months.

In a statement, chief executive Paul Stoffels highlighted Mr Huston’s role in steering the business through its current strategic overhaul, saying he "worked on the transformation of Galapagos into a focused cell therapy business leveraging our unique decentralized cell therapy platform."

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK